GlassScriptPhysician profile
Jennifer Polanic
NPI 1790167138
$2,699.44
in general payments reported to CMS, 2019-2025
24 companies · $720 in 2025
The $720 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $42.29 · 2021: $235 · 2022: $298 · 2023: $419 · 2024: $985 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,123.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $405.27 | 2020-2025 | |
| Astellas Pharma US INC | $268.43 | 2023-2024 | Veozah |
| Glaxosmithkline, LLC. | $259.51 | 2021-2024 | Arexvy |
| Astrazeneca Pharmaceuticals LP | $210.56 | 2024-2025 | Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $181.58 | 2025 | Spravato |
| Novo Nordisk INC | $178.99 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Globus Medical, INC. | $172.20 | 2025 | Vyrsa V1, Senza |
| Nevro Corp. | $171.83 | 2024 | Senza |
| Braeburn INC. | $142.72 | 2023 | Brixadi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.76 | 2022-2024 | Ofev, Jardiance |
| Abbott Laboratories | $123.28 | 2024-2025 | Esprit |
| Alkermes, INC. | $103.86 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $58.57 | 2024-2025 | Rexulti |
| Amgen INC. | $45.73 | 2022-2023 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $44.65 | 2022-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $34.47 | 2022-2023 | Mounjaro |
| Inari Medical, INC. | $31.19 | 2022 | |
| Gilead Sciences, INC. | $27.95 | 2025 | Epclusa |
| Mylan Specialty L.P. | $20.59 | 2023 | Yupelri |
| Radius Health, INC. | $20.21 | 2024 | Tymlos |
| Amarin Pharma, INC. | $19.20 | 2020 | |
| Pfizer INC. | $17.84 | 2025 | |
| Exact Sciences Corporation | $13.60 | 2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Polanic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.